HTA Methodology Shifts & Pricing Pressures

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, health economist, and it's great to have you with us today.

SaraAnd I'm Sara, market access strategy. Always good to be here — and I'll say, I've had today's topics circled since this morning. The methodological shifts are accelerating faster than many realize.

MarcusSame here. We're looking at FDA's decentralized trials guidance — the implications for real-world evidence generation are significant. Then CMS's digital therapeutics coverage policy — a real test case for value frameworks. And the Supreme Court's patent settlements decision — how that reshapes market access strategies.

SaraThat second one is particularly interesting to me. The budget impact question around digital therapeutics is one the field hasn't fully worked out yet. How do you value something that requires ongoing patient engagement?

MarcusExactly. Let's get into it.

MarcusStarting with FDA's decentralized trials guidance. The core shift is toward more flexible trial designs that incorporate digital endpoints and remote monitoring. This isn't just logistical—it fundamentally changes how we generate evidence for real-world applicability.

SaraThat's one read — I'd frame it slightly differently. The part that gives me pause is how HTA bodies will interpret these novel endpoints. There's a real risk of methodological inconsistency across jurisdictions.

MarcusWhat strikes me is the opportunity for earlier evidence generation. But I wonder if that's the full picture though? Payers will need robust validation frameworks to prevent data fragmentation.

SaraThat connects to something I keep coming back to: the burden of proof for RWE acceptance remains high. FDA guidance doesn't automatically translate to HTA credibility.

MarcusFair point. And from the payer side, the cost implications of decentralized trials could offset savings if not managed carefully. It's a double-edged sword.

SaraRight — and we haven't even touched on data privacy complexities. This is one of those stories where the regulatory tail might wag the evidence dog.

MarcusPrecisely. The tension between innovation and methodological rigor is playing out in real time.

MarcusNow to CMS's digital therapeutics coverage policy. The move toward coverage with evidence development for digital health interventions signals a pragmatic shift in how value is assessed for non-traditional modalities.

SaraThat's fair, though I think payers would see it differently. The real question is whether CMS can create sustainable pathways for these technologies without creating precedent for lower evidence thresholds across other areas.

MarcusWhat's striking here is the explicit recognition of digital engagement as a therapeutic modality. But I'd push back slightly on the sustainability angle. The administrative burden of continuous data collection could undermine long-term viability.

SaraExactly, and what's interesting is how this intersects with patient-reported outcomes. Digital tools enable real-time data capture that traditional methods can't match. But does that translate to meaningful cost offsets?

MarcusThat's the billion-dollar question. The budget impact models for these interventions are still nascent. Payers will need new analytical approaches to assess opportunity costs.

SaraHonestly, this one caught me off guard. The pace of policy development outpaces our ability to develop standardized methodologies. That creates access uncertainty.

MarcusNo question. The tension between innovation and system sustainability is acute here.

MarcusThe Supreme Court's patent settlements decision creates immediate uncertainty for branded drug pricing strategies. The ruling narrows safe harbors for settlement agreements, potentially accelerating generic competition timelines.

SaraI wonder if that's the full picture though? The decision might actually strengthen patent thickets for complex molecules. We could see more layered IP strategies emerging.

MarcusThat's a nuanced take. What's undeniable is the increased litigation risk. Companies will need to reassess their market access timelines and evidence generation windows.

SaraRight — and from the payer side, this could mean earlier access to generics but also higher prices for innovative products with strong IP positions. It's a delicate balance.

MarcusThe methodological implication is clear: HTA bodies may need to adjust their time horizons for cost-effectiveness assessments. The evidence generation landscape just shifted.

SaraThis is one of those stories where the commercial and access implications are deeply intertwined. The ripple effects will be felt across the entire value chain.

MarcusUndeniably. The question now is how companies recalibrate their evidence strategies in this new environment.

MarcusFinally, NICE's consultation on incorporating equity considerations into HTA. The proposal to adjust cost-effectiveness thresholds for health inequalities represents a fundamental shift in how value is defined.

SaraThat's one read — I'd frame it slightly differently. The operational challenges of implementing equity adjustments are substantial. How do you quantify and standardize equity weights across diverse populations?

MarcusWhat strikes me is the explicit recognition that traditional QALY thresholds may not capture the full value of treatments for underserved populations. But I'd push back slightly on the practical implementation. The methodology risks becoming overly subjective.

SaraThat's fair, though I think payers would see it differently. The budget impact question here is enormous. If equity adjustments become widespread, it could strain health system resources significantly.

MarcusExactly, and what's interesting is how this intersects with the broader value-based healthcare movement. It forces a conversation about who gets to define 'value' in the first place.

SaraThis is one of those stories where the ethical and economic dimensions collide. The consultation signals a philosophical shift that will reshape evidence requirements.

MarcusNo question. The tension between equity and efficiency will define HTA for the next decade.

SaraA lot to think about today. I'll be watching how CMS operationalizes the digital therapeutics policy — the implementation details will reveal whether this is truly transformative or just incremental change.

MarcusSame — and for me the thread running through today is the accelerating gap between regulatory innovation and HTA methodology development. That tension will shape access for years to come.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.